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Key players in translational regulationsuch as ribosomes might represent
powerful, but hitherto largely unex-
plored, targets to eliminate drug-refrac-
tory cancer stem cells (CSCs). A recent
study by the Lisanti group has docu-
mented how puromycin, an old antibi-
otic derived from Streptomyces alboniger
that inhibits ribosomal protein transla-
tion, can efficiently suppress CSC states
in tumorspheres and monolayer cultures.
We have used a closely related approach
based on Biolog Phenotype Microarrays
(PM), which contain tens of lyophilized
antimicrobial drugs, to assess the chemo-
sensitivity profiles of breast cancer cell
lines enriched for stem cell-like proper-
ties. Antibiotics directly targeting active
sites of the ribosome including emetine,
puromycin and cycloheximide, inhibitors
of ribosome biogenesis such as dactino-
mycin, ribotoxic stress agents such as
daunorubicin, and indirect inhibitors of
protein synthesis such as acriflavine, had
the largest cytotoxic impact against clau-
din-low and basal-like breast cancer cells.
Thus, biologically aggressive, treatment-
resistant breast cancer subtypes enriched
for stem cell-like properties exhibit exac-
erbated chemosensitivities to anti-proto-
zoal and anti-bacterial antibiotics
targeting protein synthesis. These results
suggest that old/existing microbicides
might be repurposed not only as new
cancer therapeutics, but also might pro-
vide the tools and molecular understand-
ing needed to develop second-generation
inhibitors of ribosomal translation to
eradicate CSC traits in tumor tissues.
Recent work from Lisanti’s group
has rekindled the interest of cancer
researchers in using “old” antibiotics
inhibiting protein synthesis as effective
drugs to eliminate cancer stem cells
(CSCs).1 CSCs are implicated in disease
recurrence and metastatic spread and
are known to be resistant to many con-
ventional therapies.2-7 In their hands,
breast CSCs were significantly enriched
for numerous ribosomal proteins and
appeared to be addicted to protein syn-
thesis. Additionally, they found that
antibiotics such as puromycin, which
competitively inhibits protein synthesis
by mimicking the 30 end of an aminoa-
cylated tRNA interacting with the A-
site of the ribosome and also by gener-
ating puromycylated-peptides and caus-
ing premature release of the peptide
chain, completely prevented CSC-
formed mammospheres in a manner
strictly dependent on the blockade of
nascent protein synthesis by ribosomes.1
Interestingly, puromycin preferentially
targeted CSC cellular states because
pre-incubation with the antibiotic in
the setting of an attached monolayer
fully prevented the later capacity of
breast cancer cell populations to form
microtumors in non-adherent non-dif-
ferentiating conditions.1
Global gene expression analyses have
allowed the delineation of 5 different
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EXTRA VIEW
intrinsic subtypes of breast cancer:
Luminal A, Luminal B, HER2-enriched,
basal-like, and the recently characterized
claudin-low group.8–11 The most aggres-
sive subtypes, claudin-low and basal-like,
have the worst mortality rate among the
intrinsic breast cancer subtypes due to
higher grade at diagnosis, predilection for
early metastasis and, importantly, lack of
targeted therapy. Basal-like and claudin-
low tumors are distinct from other breast
cancer subtypes since they possess stem
cell-like properties with high expression of
mesenchymal and epithelial-to-mesenchy-
mal (EMT) genes, which is thought to be
reflective of a least-differentiated stage of
epithelial development. Indeed, we are
amassing evidence that the claudin-low
breast cancer subtype should be viewed as
the first example of adult carcinoma
driven by aberrant reactivation of an
embryonic-like stem cell transdifferentia-
tion program.12 Basal-like and claudin-
low characteristics, which are also com-
mon in chemotherapy-resistant breast
tumors,13 might represent different extents
of reprogramming due to the aberrant
activation of EMT inducers in committed
cells (e.g., luminal progenitors).
An intimate relationship exists
between EMT, CSCs, and the claudin-
low and basal-like subtypes of breast can-
cer, representing a cell state with aggres-
sive and therapeutic resistant properties.
Given that these breast carcinoma sub-
types prominently exhibit enrichment
and hyperactivation of oncogenic signal-
ing cascades driven by c-MYC and
mTOR,14–17 2 key regulators of the
translational machinery and protein syn-
thesis, respectively, we recently hypothe-
sized that pharmacological inhibition of
deregulated protein synthesis might con-
stitute a highly conserved target in multi-
drug resistant claudin-low and basal-like
tumor cells. Moreover, because drug
repositioning (also termed re-profiling,
therapeutic switching or drug repurpos-
ing) constitutes a useful strategy to accel-
erate the drug development process, we
envisioned that one could combine both
ideas by simultaneously exploring the
cytotoxic activity of “old” antibiotics,
antimalarials, antiprotozoals or anticancer
drugs against a small panel of selected
breast cancer cell lines highly representa-
tive of human claudin-low and basal-like
tumors.
The claudin-low MDA-MB-231 and
SUM-159PT10,11 cell lines and the basal-
like HER2C JIMT-118-24 cell line were
used in a chemical sensitivity screen. We
utilized the Phenotype Microarray (PM)
system, marketed and sold by Biolog
(www.biolog.com), to measure the sensi-
tivity of these cells to a wide variety of
92 antibiotics and other growth inhibitors
in microplates (PM-M11 to PM-M14).
This approach enables the testing of tens
of phenotypes and the identification of
shared sensitivities among claudin-low
and basal-like breast cancer cells to a wide
variety of drugs (Fig. 1). We arbitrarily
grouped chemosensitivity responses of the
breast cancer cell lines into 5 categories
based on both the number of drug doses
able to induce a growth inhibition rate
greater than 50% and the number of
drug-responsive cell lines (Fig. 2). Based
on these criteria, 5 drugs showed the larg-
est cytotoxic impact on the growth of
claudin-low and basal-like cell lines: 1)
Emetine, an anti-protozoal alkaloid used
in the treatment of ameobiasis that also
displays potent anti-malarial activity, is
known to interact with the E-site of
the ribosomal small subunit and inhibit
Figure 1. Rapid screening for anti-breast cancer antibiotics using Biolog Phenotype Microarrays. Representative micrographs of Phenotype Microarray
analyses measuring tetrazolium dye reduction by MDA-MB-231, SUM-159PT, and JIMT-1 breast carcinoma cells cultured in the absence or presence of
92 antibiotics and other growth inhibitors. Red boxes denote highly active drugs in which at least 3 of the 4 graded concentrations decreased optical
density by 50 % in each individual cell line. Drug names labeled in red denote those drugs exhibiting high activity in all 3 breast cancer cell lines.
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Figure 2. Chemosensitivity map of cell line models representative of breast cancer subtypes enriched for stem cell-like properties. A color-coding
scheme assigned each drug to yellow (none of the 4 graded drug concentrations decreased cell growth by 50 %), orange (at least one of the 4 graded
concentrations decreased cell growth by 50 %), or red (at least 3 of the 4 graded concentrations decreased cell growth by 50 %) categories. Drugs
were categorized as “very high active” if the red code occurred in all 3 cell lines, “high activity” if either the red or orange codes occurred in all 3 cell lines,
“moderate activity” if either the red or orange codes occurred in 2 of the 3 cell lines, “low activity” if either the red or orange codes occurred in one of the
3 cell lines, and “no activity” when none of the color-coding categories occurred in the 3 cell lines.
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ribosome movement along mRNA,25
thus irreversibly blocking protein syn-
thesis. Two) Dactinomycin (also known
generically as actinomycin D), the first
polypeptide antibiotic shown to have
anti-cancer activity, inhibits all RNA syn-
thesis including ribosome biogenesis,
which is reflected in an inhibition of pro-
tein synthesis. Three) Puromycin inter-
acts with the A-site of the ribosome and
inhibits protein synthesis via premature
chain termination. Four) Daunorubicin
(daunomycin), a chemotherapeutic of
the anthracycline family, is a ribotoxic
stress agent that inhibits protein transla-
tion.26 Five) Acriflavine, an intercalating
antimetabolite used as a topical antisep-
tic, has been shown to rapidly inhibit
protein synthesis to exert emetine-like
amebicidal actions.
It is noteworthy that an inhibitory
capacity on protein synthesis was shared
by all the most effective antimicrobials
that efficiently inhibited growth of clau-
din-low and basal-like breast carcinoma
cells. Other well-known antibiotics capa-
ble of effectively inhibiting protein synthe-
sis such as cycloheximide, an elongation
inhibitor that binds to the E site of ribo-
somes, were among the drugs with a high
Figure 3. Inhibitors of ribosomal protein synthesis: (A)novel strategy to eradicate CSC traits in tumor tissues. Biologically aggressive, treatment-resistant
breast cancer subtypes enriched for stem cell-like properties exhibit exacerbated chemosensitivities to antibiotics directly targeting active sites of the
ribosome, such as emetine, puromycin and cycloheximide; inhibitors of ribosome biogenesis such as dactinomycin; ribotoxic stress agents such as
daunorubicin, and indirect inhibitors of protein synthesis such as acriﬂavine. The repurposing of these old/existing microbicides and the development of
second-generation inhibitors of ribosomal translation might constitute a valuable strategy to eradicate CSC traits in tumor tissues.
3530 Volume 14 Issue 22Cell Cycle
activity profile against claudin-low and
basal-like breast carcinomas (Fig. 2).
Although cancer cell lines representative
of other breast cancer subtypes (e.g.,,
Luminal A/B, HER2-enriched) were not
included in the sensitivity screen, it is
notable that when the same Biolog Pheno-
type Microarray was used to profile
HER2-enriched SKBR3 cells, reagents
such as berberine chloride, azathioprine,
celastrol, gossypol, miltefosine, and etopo-
side, were found to have the largest growth
impact on the cell line.27 It is therefore
reasonable to assume that an intrinsic
hypersensitivity to antimicrobial inhibi-
tors of protein synthesis might occur in
biologically aggressive and chemoresistant
claudin-low and basal-like breast cancer
cells.
Cellular translation is receiving increas-
ing attention in anti-cancer therapy, with
key translation regulatory factors such as
ribosomes emerging as feasible tar-
gets.28,29 In this scenario, drug repurpos-
ing can circumvent the high cost of drug
discovery and development, the high fail-
ure rates and the long duration to develop
novel treatments.30,31 Using Phenotype
MicroArrays, which enables quantitative
measurements of thousands of cellular
phenotypes at the same time, we show
that breast cancer subtypes enriched for
stem cell-like properties display exacer-
bated chemical sensitivities to microbi-
cides that target ribosomes and/or inhibit
protein synthesis (Fig. 3). These findings
suggest that classical anti-protozoal and
anti-bacterial antibiotics, such as emetine,
puromycin or acriflavine, could be used in
combination with the currently used con-
ventional cytotoxic chemotherapy in the
treatment of claudin-low and basal-like
breast carcinomas. Moreover, our ever-
growing mechanistic understanding of
ribosome functioning might guide the
design of future small molecule inhibitors
to target eukaryotic translation, which
might be closely involved with the acquisi-
tion of molecular and functional traits of
CSCs. As exemplified for the anti-proto-
zoal alkaloid emetine, now repurposed as
an anti-malarial based on the elucidation
of how emetine binds to the ribosome,25
and which has already been shown to
selectively inhibit glioblastoma stem cells-
enriched cultures,32 it might be possible
for drug manufacturers to chemically
modify natural antibiotics to further
enhance their potency and specificity as
translation inhibitors capable of eradicat-
ing CSC traits in tumor tissues.
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